9-[2-(4-Fluoro-2-methoxy-phenyl)-2-hydroxy-ethyl]-7,7-dimethyl-2-pyrimidin-4-yl-6,7,8,9-tetrahydro-pyrimido[1,2-a] pyrimidin-4-one | 502928-01-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: 9-[2-(4-Fluoro-2-methoxy-phenyl)-2-hydroxy-ethyl]-7,7-dimethyl-2-pyrimidin-4-yl-6,7,8,9-tetrahydro-pyrimido[1,2-a] pyrimidin-4-one
• 英文别名: 9-[2-(4-Fluoro-2-methoxyphenyl)-2-hydroxyethyl]-7,7-dimethyl-2-pyrimidin-4-yl-6,8-dihydropyrimido[1,2-a]pyrimidin-4-one
• CAS: 502928-01-0
• 化学式: C₂₂H₂₄FN₅O₃
• 分子量: 425.463
• InChiKey: ADVSIMKBVPUUOQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  31
• 可旋转键数：
  5
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  91.2
• 氢给体数：
  1
• 氢受体数：
  7

文献信息

• 2-pyrimidinyl-6,7,8,9-tetrahydropyrimido[1,2-a]Pyrimidin-4-one and 7-Pyrimidinyl-2,3-Dihydroimidazo[1,2-a]Pyrimidin-5(1H)one derivatives
  申请人：SANOFI-SYNTHELABO

  公开号：EP1295884A1

  公开（公告）日：2003-03-26

  The invention relates to a pyrimidone derivative represented by formula (I) or a salt thereof: wherein: X represents two hydrogen atoms, a sulphur atom, an oxygen atom or a C1-2 alkyl group and a hydrogen atom; Y represents a bond, a ethenylene group, a ethynylene group, a an oxygen atom, a sulphur atom, a sulfonyl group, a sulfoxide group, a carbonyl group, a nitrogen atom being optionally substituted by a C1-6 alkyl group, a phenyl or a benzyl group; or a methylene group optionally substituted; R1 represents a pyrimidine group;    when Y represents a bond, a methylene group optionally substituted or a carbonyl group then R2 represents a C1-6 alkyl group optionally substituted by a C6,10 aryloxy or a C6,10 arylamino group ; a C 3-6 cycloalkyl group, a C1-4 alkylthio group, a C1-4 alkoxy group, a C1-2 perhalogenated alkyl group, a C1-3 halogenated alkyl group, a phenylthio group, a benzyl group, a phenyl ring, a 5,6,7,8-tetrahydronaphthyl ring, a naphthyl ring, a pyridyl ring, a pyrrole ring, a thiophene ring, a furan ring or an imidazole ring ;    when Y represents a double bond, a triple bond, an oxygen atom, a sulphur atom, a sulfonyl group, a sulfoxyde group or a nitrogen atom being optionally substituted then R2 represents a C1-6 alkyl group (optionally substituted by a C6,10 aryloxy or a C6,10 arylamino group), a C3-6 cycloalkyl group, a C1-2 perhalogenated alkyl group, a C1-3 halogenated alkyl group, a benzyl group, a phenyl ring, a 5,6,7,8-tetrahydronaphthyl ring, a naphthyl ring, a pyridyl ring, a pyrrole ring, a thiophene ring, a furan ring or an imidazole ring ; R3 and R4 represents each independently a hydrogen atom, C1-6 alkyl group, a hydroxy group, a C1-4 alkoxy group or a halogen atom; R5 represents a hydrogen atom, a C1-6 alkyl group or a halogen atom; The invention relates also to a medicament comprising the said derivative or a salt thereof as an active ingredient which is used for preventive and/or therapeutic treatment of a neurodegenerative disease caused by abnormal activity of GSK3β or GSK3β and cdk5/p25, such as Alzheimer disease.

  本发明涉及一种由式(I)表示的嘧啶酮衍生物或其盐： 其中： X代表两个氢原子、硫原子、氧原子或C1-2烷基和一个氢原子； Y代表一个键、一个乙烯基、一个乙炔基、一个氧原子、一个硫原子、一个磺酰基、一个亚磺酸基、一个羰基、一个氮原子，该氮原子可选择地被C1-6烷基、苯基或苄基取代；或一个可选择地取代的亚甲基基团； R1代表一个嘧啶基团； 当Y代表一个键、一个可选择地取代的亚甲基基团或一个羰基时，R2代表一个C1-6烷基，可选择地被C6,10芳氧基或C6,10芳基氨基基团取代；一个C3-6环烷基、一个C1-4烷基硫基、一个C1-4烷氧基、一个C1-2全卤代烷基、一个C1-3卤代烷基、一个苯硫基、一个苄基、一个苯环、一个5,6,7,8-四氢萘环、一个萘环、一个吡啶环、一个吡咯环、一个噻吩环、一个呋喃环或一个咪唑环； 当Y代表一个双键、一个三键、一个氧原子、一个硫原子、一个磺酰基、一个亚磺酸基或一个可选择地取代的氮原子时，R2代表一个C1-6烷基（可选择地被C6,10芳氧基或C6,10芳基氨基基团取代）、一个C3-6环烷基、一个C1-2全卤代烷基、一个C1-3卤代烷基、一个苄基、一个苯环、一个5,6,7,8-四氢萘环、一个萘环、一个吡啶环、一个吡咯环、一个噻吩环、一个呋喃环或一个咪唑环； R3和R4各自独立地代表一个氢原子、C1-6烷基、一个羟基、一个C1-4烷氧基或一个卤原子； R5代表一个氢原子、一个C1-6烷基或一个卤原子； 本发明还涉及一种药物，该药物包括上述衍生物或其盐作为活性成分，用于预防和/或治疗由GSK3β或GSK3β和cdk5/p25的异常活性引起的神经退行性疾病，例如阿尔茨海默病。
• Substituted 2-pyrimidinyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one and 7-pyrimidinyl-2,3-dihydroimidazo[1,2-a]pyrimidin-5(1h)one derivatives for neurodegenerative disorders
  申请人：——

  公开号：US20040266793A1

  公开（公告）日：2004-12-30

  The invention relates to a pyrimidone derivative represented by formula (I) or a salt thereof wherein: X represents two hydrogen atoms, a sulphur atom, an oxygen atom or a C 1-2 alkyl group and a hydrogen atom; y represents a bond, an ethenylene group, an ethynylene group, an oxygen atom, a sulphur atom, a sulfonyl group, a sulfoxide group, a carbonyl group, a nitrogen atom being optionally; or a methylene group optionally substituted; R1 represents a pyrimidine group optionally substituted; R2 may represent a C 1-6 alkyl group optionally substituted by a C 6,10 aryloxy or a C 6,10 arylamino group; a C 3-6 cycloalkyl group, a C 1-4 alkylthio group, a C 1-4 alkoxy group, a C 1-2 perhalogenated alkyl group, a C 1-3 halogenated alkyl group, a phenylthio group, a benzyl group, a benzene ring, an indan ring, a 5,6,7,8-tetrahydronaphthalene ring, a naphthalene ring, a pyridine ring, a pyrrole ring, a thiophene ring, a furan ring or an imidazole ring; R3 and R4 represents each independently a hydrogen atom, C 1-6 alkyl group, a hydroxy group, a C 1- 4 alkoxy group or a halogen atom; R5 represents a hydrogen atom, a C 1-6 alkyl group or a halogen atom. The invention relates also to a medicament comprising the said derivative or a salt thereof as an active ingredient which is used for preventive and/or therapeutic treatment of a neurodegenerative disease caused by abnormal activity of GSK3&bgr;3 or GSK3&bgr;3 and cdk5/p25, such as Alzheimer disease. 1

  本发明涉及一种由式（I）表示的嘧啶酮衍生物或其盐，其中：X代表两个氢原子，硫原子，氧原子或C1-2烷基和氢原子；y代表键，乙烯基，乙炔基，氧原子，硫原子，磺酰基，亚磺酸基，羰基，氮原子（可选）或取代的亚甲基基团；R1表示可选取代的嘧啶基团；R2可以代表C1-6烷基，可选地被C6,10芳氧基或C6,10芳基氨基基团取代；C3-6环烷基，C1-4烷基硫基，C1-4烷氧基，C1-2全氟烷基，C1-3卤代烷基，苯硫基，苄基，苯环，茚环，5,6,7,8-四氢萘环，萘环，吡啶环，吡咯环，噻吩环，呋喃环或咪唑环；R3和R4各自独立地表示氢原子，C1-6烷基，羟基，C1-4烷氧基或卤素原子；R5表示氢原子，C1-6烷基或卤素原子。本发明还涉及一种药物，其中包括所述衍生物或其盐作为活性成分，用于预防和/或治疗由GSK3β3或GSK3β3和cdk5/p25的异常活性引起的神经退行性疾病，例如阿尔茨海默病。
• Use of Substituted 2-Pyrimidinyl-6,7,8,9-tetrahydropyrimido[1,2-A] Pyrimidin-4-one and 7-Pyrimidinyl-2,3-dihydroimidazo[1,2-A] Pyrimidin-5(1H)one Derivatives
  申请人：Gallet Thierry

  公开号：US20080269257A1

  公开（公告）日：2008-10-30

  The invention relates to use of a pyrimidone derivative represented by formula (I) or a salt thereof as therapeutic agents: Wherein m, n, p, X, Y, R1, R2, R3, R4 R5, are as defined herein. The invention specifically relates to a medicament comprising the said derivative or a salt thereof as an active ingredient which is used for preventive and/or therapeutic treatment of a neurodegenerative disease caused by abnormal activity of GSK3β or GSK3β and cdk5/p25, such as Alzheimer disease.

  该发明涉及使用式（I）所表示的嘧啶酮衍生物或其盐作为治疗剂：其中m、n、p、X、Y、R1、R2、R3、R4、R5如本文中所定义。该发明特别涉及一种药物，包括所述衍生物或其盐作为活性成分，用于预防和/或治疗由GSK3β或GSK3β和cdk5/p25异常活性引起的神经退行性疾病，例如阿尔茨海默病。
• Substituted 2-pyrimidinyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one and 7-pyrimidinyl-2,3-dihydroimidazo[1,2-a]pyrimidin-5(1H)one derivatives
  申请人：SANOFI-SYNTHELABO

  公开号：EP1340760A1

  公开（公告）日：2003-09-03

  The invention relates to a pyrimidone derivative represented by formula (I) or a salt thereof: wherein: X represents two hydrogen atoms, a sulphur atom, an oxygen atom or a C1-2 alkyl group and a hydrogen atom; Y represents a bond, a ethenylene group, a ethynylene group, an oxygen atom, a sulphur atom, a sulfonyl group, a sulfoxide group, a carbonyl group, a nitrogen atom being optionally; or a methylene group optionally substituted; R1 represents a pyrimidine group optionally substituted; R2 may represent a C1-6 alkyl group optionally substituted by a C6,10 aryloxy or a C6,10 arylamino group ; a C3-6 cycloalkyl group, a C1-4alkylthio group, a C1-4alkoxy group, a C1-2 perhalogenated alkyl group, a C1-3 halogenated alkyl group, a phenylthio group, a benzyl group, a phenyl ring, an indanyl ring, a 5,6,7,8-tetrahydronaphthyl ring, a naphthyl ring, a pyridine ring, a pyrrole ring, a thiophene ring, a furan ring or an imidazole ring ; R3 and R4 represents each independently a hydrogen atom, C1-6 alkyl group, a hydroxy group, a C1-4alkoxy group or a halogen atom; R5 represents a hydrogen atom, a C1-6 alkyl group or a halogen atom; The invention relates also to a medicament comprising the said derivative or a salt thereof as an active ingredient which is used for preventive and/or therapeutic treatment of a neurodegenerative disease caused by abnormal activity of GSK3β or GSK3β and cdk5/p25, such as Alzheimer disease.

  本发明涉及式 (I) 所代表的嘧啶酮衍生物或其盐： 其中 X 代表两个氢原子、一个硫原子、一个氧原子或一个 C1-2 烷基和一个氢原子； Y 代表一个键、一个乙烯基、一个乙炔基、一个氧原子、一个硫原子、一个磺酰基、一个亚砜基、一个羰基、一个任选被取代的氮原子或一个任选被取代的亚甲基； R1 代表任选被取代的嘧啶基团； R2 可代表被 C6,10 芳氧基或 C6,10 芳酰胺基任选取代的 C1-6 烷基；C3-6环烷基、C1-4烷硫基、C1-4烷氧基、C1-2过卤代烷基、C1-3卤代烷基、苯硫基、苄基、苯基环、茚基环、5,6,7,8-四氢萘环、萘基环、吡啶环、吡咯环、噻吩环、呋喃环或咪唑环； R3 和 R4 各自独立地代表氢原子、C1-6 烷基、羟基、C1-4 烷氧基或卤素原子； R5 代表氢原子、C1-6 烷基或卤原子； 本发明还涉及一种包含上述衍生物或其盐作为活性成分的药物，该药物用于预防和/或治疗由 GSK3β 或 GSK3β 和 cdk5/p25 活性异常引起的神经退行性疾病，如阿尔茨海默病。
• SUBSTITUTED 2-PYRIMIDINYL-6,7,8,9-TETRAHYDROPYRIMIDO[1,2-A]PYRIMIDIN-4-ONE AND 7-PYRIMIDINYL-2,3-DIHYDROIMIDAZO[1,2-A]PYRIMIDIN-5(1H)ONE DERIVATIVES FOR NEURODEGENERATIVE DISORDERS
  申请人：Sanofi-Aventis

  公开号：EP1430056B1

  公开（公告）日：2005-10-26